The Hamilton Anxiety Rating Scale (HAM-A), developed by Max Hamilton in 1959, is one of the most established and widely used observer-rated instruments for…
Questions
14
Duration
20 min
Original title
HAM-A — Hamilton Anxiety Rating Scale
Adaptation
Hamilton Anxiety Rating Scale
Authors
Hamilton, M.
Created
1959
The Hamilton Anxiety Rating Scale (HAM-A), developed by Max Hamilton in 1959, is one of the most established and widely used observer-rated instruments for quantifying anxiety severity. Rather than providing a diagnostic label, this structured measure allows mental health professionals to map the exact profile and intensity of a patient's anxious distress, which often serves as a strong foundation for a cognitive case formulation. It covers both the psychological features of anxiety, such as apprehension and cognitive tension, and the diverse physiological manifestations that often accompany it.
Administered through a semi-structured interview, the HAM-A relies on the clinician's expertise to weigh the frequency, severity, and functional impact of each symptom cluster. This makes it an invaluable tool for establishing a baseline during an initial intake, especially when exploring CBT maintaining processes that keep the anxiety active. By distinguishing between psychic and somatic anxiety, the measure helps tailor interventions and provides a highly reliable metric for monitoring symptom reduction over the course of treatment.
Example result
Fictitious result, computed from a sample set of answers.
Overall score
26/ 56
The HAM-A is a clinician-administered rating scale, scored following a semi-structured interview, used to assess the severity of anxiety symptoms in adults. It comprises 14 items evaluating psychic anxiety (anxious mood, tension, fears, insomnia, cognitive symptoms, depressed mood, behavior at interview) and somatic anxiety (muscular, sensory, cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic). It is widely utilized in clinical practice and research, particularly to assess the efficacy of therapeutic and pharmacological interventions.
0–7
Absent or minimal anxiety
8–14
Mild anxiety
15–23
Moderate anxiety
24–56
Severe anxiety
26
Level typically found in patients enrolled in generalized anxiety disorder trials.
Scoring
Sum (total score and psychic/somatic subscale scores), total score ranging from 0 to 56, each item rated on a 5-point scale (from 0 to 4).
Psychic anxiety
13/ 28
Psychological component of anxiety: tension, worry, fears, mood, and behavior.
items1, 2, 3, 4, 5, 6, 14
13
028
Somatic anxiety
13/ 28
Physical manifestations of anxiety: muscle tension, sensory, cardiovascular, respiratory, gastrointestinal, genitourinary, and autonomic symptoms.
items7, 8, 9, 10, 11, 12, 13
13
028
Have your patient take this test
Assign it in one click: your patient answers on their phone, you receive the score and its interpretation.
The HAM-A provides a comprehensive evaluation of anxiety by breaking it down into 14 distinct symptom clusters, capturing both the subjective experience and the physical toll of anxiety.
Psychic anxiety: Captures mental agitation, including anxious mood, generalized fears, tension, cognitive difficulties, and depressed mood, which often require challenging negative thoughts in therapy.
Somatic anxiety: Covers physical manifestations across multiple systems, including muscular tension, sensory disturbances, and cardiovascular, respiratory, gastrointestinal, and genitourinary symptoms.
Autonomic arousal: Identifies physiological signs of a sensitized nervous system, such as sweating, flushing, and dry mouth.
Observable behavior: Integrates the clinician's direct observation of the patient's restlessness, facial expressions, and physical tension during the consultation.
This scale is specifically designed for adults and is particularly relevant for individuals presenting with symptoms of generalized anxiety disorder or those who need help distinguishing between adaptive vs maladaptive coping.
When and why to use it
Clinicians typically integrate the HAM-A into their practice to objectify the severity of anxious distress and track changes systematically.
Intake baseline: To map out the specific cognitive and physiological profile of the patient's anxiety at the start of therapy, informing the broader longitudinal case formulation.
Monitoring change: To evaluate the effectiveness of psychological or pharmacological interventions by tracking score reductions over time alongside between-session anxiety self-monitoring.
Symptom differentiation: To distinguish whether the patient's presentation is predominantly driven by mental apprehension or somatic hyperarousal, helping orient the treatment plan.
Clinical severity thresholding: To compare the patient's current distress against established clinical cut-offs for mild, moderate, or severe anxiety.
Using a validated clinician-rated score provides a much sharper picture than self-reporting alone, as it filters the patient's subjective experience through clinical observation.
Clinical library
750+ clinical tools
A library built with and for clinicians, ready to use in session and extend between appointments.
To be completed by the clinician following a semi-structured interview. For each of the 14 items, rate the overall intensity of the symptom over the recent period (usually the past week) on a scale from 0 (not present) to 4 (very severe / incapacitating), taking into account frequency, intensity, and functional impact.
This item focuses on heart-related autonomic symptoms and vascular sensations.
Absent
Mild
Moderate
Severe
Very severe / incapacitating
10. Respiratory symptoms: heaviness in the chest or feelings of constriction, choking sensations, sighing, dyspnea (shortness of breath).
This item captures breathing difficulties and subjective feelings of chest constriction.
Absent
Mild
Moderate
Severe
Very severe / incapacitating
11. Gastrointestinal symptoms: difficulty swallowing, swallowing air, indigestion, pain before or after meals, burning sensations, abdominal bloating, nausea, vomiting, gurgling, diarrhea, weight loss, constipation.
This item covers digestive distress and autonomic effects on the stomach and bowels.
Absent
Mild
Moderate
Severe
Very severe / incapacitating
12. Genitourinary symptoms: frequent or urgent urination, amenorrhea (absence of menstruation), menorrhagia (heavy menstrual bleeding), development of frigidity, premature ejaculation, lack of erection, impotence.
This item assesses anxiety-induced disruptions to the urinary tract and sexual functioning.
Absent
Mild
Moderate
Severe
Very severe / incapacitating
13. Autonomic nervous system symptoms: dry mouth, flushing, pallor, tendency to sweat, dizziness, tension headaches, piloerection (goosebumps).
This item groups together general signs of autonomic nervous system hyperarousal.
Absent
Mild
Moderate
Severe
Very severe / incapacitating
14. Behavior during the interview: tense, ill-at-ease, nervous hand movements (fidgeting, clenching fists), trembling, furrowed brow, tense face, sighing or rapid breathing, facial pallor, swallowing, belching, brisk tendon reflexes, dilated pupils, bulging eyes, sweating, eyelid twitching.
This item is based entirely on the clinician's direct observation of the patient's nonverbal communication and physical state during the assessment.